Abbott, a global health care company, specializes in the discovery of new medicines, technologies and health management solutions. Their product line ranges from nutritional products to laboratory diagnostics and pharmaceutical therapies for patients of all ages. Abbott is known for their global reach and their rich 120+ year history of advancing medical science, allowing millions of people live healthier, longer lives. Currently, Abbott employs over 90,000 employees around the globe working to fulfill their motto “Turning Science Into Caring”.
Since its inception in 1987, Gilead Sciences has worked to discover, develop and commercialize medications in order to improve the care of patients suffering from life-threatening diseases in various areas of unmet medical needs.
Gilead has become a leading biopharmaceutical company, and a growing pipeline of investigational drugs. The company currently markets 13 different products and employs over 4,000 dedicated professionals worldwide. Gilead is known for their specific focus on HIV/AIDS, liver disease and serious cardiovascular/metabolic and respiratory conditions.
Actelion LTD., was founded in 1997 and is currently one of the world’s leading biopharmaceutical companies. Their headquarters are located in Allschwil/Basel, Switzerland. Actelion’s first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension.
Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the US, the European Union, Japan, Canada, Australia and Switzerland. Actelion employs over 2,400 employees. Their focus lies on the discovery, development and marketing of innovative drugs for significant unmet medical needs.
Celgene is a global biopharmaceutical company focused on the discovery, development, and commercialization of products for the treatment of cancer and other severe, immune and inflammatory conditions. Celgene’s unique compounds have been used in over 300 different clinical trials at major medical centers worldwide.
Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin’s lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. Celgene gives back to the community by offering a patient-centered service helping to bridge their discoveries and advances to those that need it most by providing information, support and access to their innovative therapies to those in need.
Reckitt Benckiser is a world leader in the global household, health and personal care sectors representing big-name brands, including: Vanish, Durex, Lysol, Scholl and Veet. Reckitt Benckiser is a global leader in the markets and categories in which they compete.
The company operates in over 60 countries and their brands are sold in nearly 200 countries. They employ over 25,000 professionals and currently are ranked in the top 25 companies on London’s FTSE index. Globally, Reckitt Benckiser sold 20 million products a day in 2010.
GE Healthcare provides transformational medical technologies that help to shape a new age of patient care. GE Healthcare’s expertise in medical imaging, information technologies and medical diagnostics helps clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease to ensure that their patients can live life to its fullest.
Fresenius is a global health care group specializing in products and services for dialysis treatment, including products used in both hospital and home. The Fresenius Group is made up of the following four business segments; Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. In 2010, the group’s sales were approximately €16.0 billion. As of March 2011, the Fresenius Group employed 140,111 employees across the globe.
Agilent Technologies Inc. is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. Agilent offers the largest range of innovative measurement solutions in the industry. The company is compromised of three business divisions: Chemical Analysis, Life Sciences and Electronic Measurement. The company is committed to enabling their customers and partners to become leaders in their respective fields. Currently, Agilent employs over 18,500 professionals and caters to client in over 100 countries. In 2010, Agilent reported net revenues of $5.4 billion.
QIAGEN is the leading provider of sample and assay technologies and have developed over 500 consumable products and automated solutions. The company provides these products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes including forensics, animal or food testing and pharmaceutical process control.
QIAGEN’s assay technologies include one of the broadest ranges of molecular diagnostic tests available worldwide. Their tests include the digene HPV Test, regarded as a “gold standard” in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,500 people in over 35 locations worldwide.
Alexion is a global biopharmaceutical company that combines groundbreaking science with an unwavering commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients.
Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, the European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Novartis Vaccines and Diagnostics
Novartis Vaccines and Diagnostics is a division of Novartis, which focuses specifically on the development of preventive treatments. Novartis Vaccines and Diagnostics are the world’s fifth-largest vaccine manufacturer and second-largest supplier of flu vaccines in the United States. The division’s products also include meningococcal, pediatric and travel vaccines.